{"id":77413,"date":"2026-04-29T13:48:13","date_gmt":"2026-04-29T19:48:13","guid":{"rendered":"https:\/\/trimrx.com\/blog\/sermorelin-contraindications\/"},"modified":"2026-04-29T13:48:13","modified_gmt":"2026-04-29T19:48:13","slug":"sermorelin-contraindications","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/sermorelin-contraindications\/","title":{"rendered":"Sermorelin Contraindications \u2014 Safety Guidelines Explained"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Sermorelin Contraindications \u2014 Safety Guidelines Explained<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Fewer than 15% of patients seeking growth hormone secretagogue therapy receive adequate screening for contraindications before starting sermorelin. Not because prescribers don&#39;t care, but because many telehealth protocols rely on patient-reported histories without access to complete medical records. The result: patients with active malignancy, uncontrolled proliferative diabetic retinopathy, or recent pituitary surgery sometimes receive sermorelin prescriptions that should never have been written. The consequences aren&#39;t theoretical. Growth hormone secretagogues can accelerate tumor growth in oncology patients and worsen retinal neovascularisation in diabetics with advanced eye disease.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has guided hundreds of patients through sermorelin eligibility assessments over the past three years. The gap between &#39;technically eligible&#39; and &#39;medically appropriate&#39; comes down to understanding sermorelin contraindications at a mechanistic level. Not just memorising a list of conditions.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What are the main sermorelin contraindications?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin contraindications include active or recent cancer (within 5 years of remission), uncontrolled diabetes with proliferative retinopathy, pregnancy and breastfeeding, hypersensitivity to growth hormone-releasing hormone analogs, and critical illness requiring ICU-level care. Absolute contraindications stem from sermorelin&#39;s mechanism: stimulating pituitary growth hormone release can promote cellular proliferation in malignant tissue, worsen vascular complications in diabetic retinopathy, and cause unpredictable metabolic effects during acute physiological stress. Relative contraindications. Such as mild hypothyroidism or well-controlled diabetes. Require dose adjustment and closer monitoring rather than complete avoidance.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Most patients assume sermorelin is safe because it&#39;s a peptide that stimulates natural growth hormone production rather than replacing it with exogenous hormone. That reasoning misses the critical point: stimulating endogenous growth hormone release still produces systemic growth hormone elevation. The source differs, but the downstream effects on insulin sensitivity, cellular proliferation, and metabolic regulation remain identical to exogenous GH. This article covers the full spectrum of sermorelin contraindications, the biological mechanisms that make each condition high-risk, and the clinical decision framework prescribers use to determine eligibility when contraindications exist in borderline cases.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Understanding Sermorelin&#39;s Mechanism and Why Contraindications Matter<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin acetate is a synthetic analog of growth hormone-releasing hormone (GHRH), a 29-amino-acid peptide that binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. When sermorelin binds these receptors, it triggers a signaling cascade that increases intracellular cyclic AMP (cAMP), which in turn stimulates transcription and release of stored growth hormone from pituitary granules. Unlike exogenous growth hormone replacement. Which suppresses endogenous production through negative feedback. Sermorelin preserves the hypothalamic-pituitary axis by working within the body&#39;s natural regulatory pathways.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The clinical appeal of this mechanism is preservation of pulsatile GH secretion patterns. Exogenous GH administered as a daily subcutaneous injection creates supraphysiological peaks followed by troughs. Disrupting the normal ultradian rhythm of growth hormone release that occurs during deep sleep and postprandial periods. Sermorelin maintains physiological pulsatility because it amplifies existing release signals rather than replacing them. The trade-off: sermorelin&#39;s efficacy depends entirely on functional pituitary tissue and intact hypothalamic regulation, meaning patients with pituitary damage, prior pituitary surgery, or primary pituitary insufficiency will not respond to sermorelin therapy.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin contraindications exist because growth hormone. Whether endogenous or exogenous. Exerts powerful metabolic and proliferative effects across multiple organ systems. GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1), the primary mediator of growth hormone&#39;s anabolic effects. IGF-1 promotes cellular proliferation, inhibits apoptosis, and enhances protein synthesis. Effects that are beneficial in healthy tissue but dangerous in malignant cells, pre-malignant lesions, and pathological vascular proliferation. The FDA has never approved sermorelin for anti-aging or wellness applications; it was approved in 1997 exclusively for diagnostic assessment of growth hormone secretion in children with suspected GH deficiency, then withdrawn from the US market in 2008 when the manufacturer ceased production. Current sermorelin use occurs almost entirely through compounding pharmacies operating under state pharmacy board regulations.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Absolute Sermorelin Contraindications \u2014 Conditions Requiring Complete Avoidance<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Active malignancy represents the most critical sermorelin contraindication. Growth hormone and IGF-1 stimulate cellular proliferation through activation of the PI3K\/AKT and MAPK signaling pathways. The same pathways that drive uncontrolled growth in cancer cells. Clinical evidence from growth hormone replacement studies shows accelerated tumor progression in patients with pre-existing malignancies, and case reports document recurrence of previously treated cancers during GH therapy. The contraindication extends to patients in active treatment (chemotherapy, radiation, immunotherapy) and those within five years of achieving remission. The standard oncology threshold for declaring a patient &#39;cured.&#39; Patients with a remote cancer history (more than five years post-remission) require oncology clearance before sermorelin initiation.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Proliferative diabetic retinopathy is an absolute sermorelin contraindication because IGF-1 promotes neovascularisation. The abnormal growth of fragile blood vessels on the retinal surface that characterises advanced diabetic eye disease. These vessels are prone to rupture, causing vitreous haemorrhage and retinal detachment. Growth hormone elevation worsens this process by accelerating VEGF (vascular endothelial growth factor) production, which drives further vascular proliferation. The contraindication is specific to proliferative retinopathy; non-proliferative diabetic retinopathy (earlier-stage microvascular changes without neovascularisation) is a relative contraindication requiring ophthalmology evaluation before starting sermorelin.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Pregnancy and breastfeeding are absolute sermorelin contraindications due to insufficient safety data and theoretical risk of altering foetal or neonatal growth patterns. Growth hormone and IGF-1 cross the placental barrier and appear in breast milk. Exposing the developing foetus or nursing infant to supraphysiological growth factor levels. No controlled trials have assessed sermorelin safety in pregnant or lactating women, and the compound carries Pregnancy Category C classification (animal studies show adverse effects; human data absent). Women of childbearing age initiating sermorelin should use reliable contraception and discontinue the medication immediately upon confirmed pregnancy.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Relative Sermorelin Contraindications \u2014 Conditions Requiring Caution and Monitoring<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Uncontrolled diabetes mellitus. Defined as HbA1c above 8.5% or fasting glucose consistently above 180 mg\/dL. Is a relative sermorelin contraindication. Growth hormone opposes insulin action by promoting hepatic gluconeogenesis and reducing peripheral glucose uptake, effects that can worsen glycaemic control in patients whose diabetes is already poorly managed. The clinical concern is not hyperglycaemia alone but the risk of diabetic ketoacidosis (DKA) in type 1 diabetics or hyperosmolar hyperglycaemic state (HHS) in type 2 diabetics if insulin resistance worsens acutely. Patients with well-controlled diabetes (HbA1c below 7.5%) can use sermorelin with dose adjustments to insulin or oral hypoglycaemic agents and more frequent glucose monitoring during titration.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Hypothyroidism. Particularly untreated or undertreated cases. Represents a relative sermorelin contraindication because thyroid hormone is required for normal growth hormone receptor expression and IGF-1 synthesis. Patients with subclinical hypothyroidism (TSH 4.5\u201310 mIU\/L with normal free T4) may experience blunted sermorelin response; those with overt hypothyroidism (TSH above 10 mIU\/L or low free T4) will see minimal benefit until thyroid function normalizes. The standard protocol: optimize thyroid replacement therapy first, confirm TSH below 3.0 mIU\/L, then initiate sermorelin. Concurrent thyroid hormone and sermorelin therapy is safe once euthyroid status is achieved.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Critical illness and acute physiological stress. Sepsis, major surgery, trauma, acute respiratory failure requiring mechanical ventilation. Are temporary sermorelin contraindications. During critical illness, the body enters a catabolic state characterised by elevated cortisol, suppressed GH receptor expression, and GH resistance (normal or elevated GH levels with low IGF-1). Administering sermorelin during this phase produces unpredictable metabolic effects and offers no therapeutic benefit because the GH-IGF-1 axis is already maximally stressed. The contraindication resolves once the acute illness resolves and metabolic homeostasis is restored. Typically 4\u20136 weeks post-discharge from ICU-level care.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Sermorelin Contraindications: Comparison of Risk Levels and Clinical Management<\/h2>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Condition<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Contraindication Type<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Primary Mechanism of Risk<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Clinical Management<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Active malignancy (any site)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Absolute<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">IGF-1 stimulates cancer cell proliferation via PI3K\/AKT pathway; accelerates tumor growth<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Sermorelin prohibited until 5 years post-remission; oncology clearance required<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Highest risk. No exceptions<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Proliferative diabetic retinopathy<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Absolute<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">IGF-1 promotes retinal neovascularisation; increases risk of vitreous haemorrhage and retinal detachment<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Requires ophthalmology exam; sermorelin permitted only after laser photocoagulation stabilises retinopathy<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Vision-threatening; strict screening required<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Pregnancy\/breastfeeding<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Absolute<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Foetal\/neonatal exposure to supraphysiological GH and IGF-1; insufficient human safety data<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Discontinue immediately upon confirmed pregnancy; use reliable contraception during therapy<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Precautionary. No controlled trial data<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Uncontrolled diabetes (HbA1c &gt;8.5%)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Relative<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">GH opposes insulin; worsens hyperglycaemia and insulin resistance<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Optimize glycaemic control first; increase insulin doses during sermorelin titration; monitor glucose 2\u20133\u00d7\/day<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Manageable with close monitoring<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Hypothyroidism (TSH &gt;4.5 mIU\/L)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Relative<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Thyroid hormone required for GH receptor expression; blunted sermorelin response if undertreated<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Optimize levothyroxine dose first; target TSH &lt;3.0 mIU\/L before starting sermorelin<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Reduces efficacy more than safety risk<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Critical illness (ICU-level care)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Temporary<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">GH resistance during acute stress; unpredictable metabolic effects; no therapeutic benefit<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Delay sermorelin until 4\u20136 weeks post-discharge; reassess metabolic stability<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Wait until recovery. Not urgent therapy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Sermorelin contraindications exist because growth hormone stimulation produces systemic proliferative and metabolic effects. Therapeutic in healthy patients but dangerous in malignancy, diabetic retinopathy, and critical illness.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Active cancer within the past five years is an absolute contraindication; IGF-1 accelerates tumor growth through the PI3K\/AKT pathway, making sermorelin therapy unsafe until oncology clearance confirms long-term remission.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Proliferative diabetic retinopathy requires ophthalmology evaluation before sermorelin initiation. IGF-1 promotes retinal neovascularisation, which increases vitreous haemorrhage and vision loss risk.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Uncontrolled diabetes (HbA1c above 8.5%) is a relative contraindication; growth hormone opposes insulin action and can worsen hyperglycaemia, requiring dose adjustments and closer glucose monitoring during therapy.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Pregnancy and breastfeeding are absolute contraindications due to insufficient safety data and theoretical risk of altering foetal or neonatal growth patterns through placental and breast milk IGF-1 transfer.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Hypothyroidism blunts sermorelin response because thyroid hormone is required for growth hormone receptor expression. Optimize TSH below 3.0 mIU\/L before starting therapy to ensure meaningful clinical benefit.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Sermorelin Contraindications Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Have a Family History of Cancer but No Personal Diagnosis?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Family history of cancer is not a sermorelin contraindication unless you carry a known hereditary cancer syndrome (BRCA mutation, Lynch syndrome, familial adenomatous polyposis). A first-degree relative with breast, colon, or prostate cancer increases your lifetime cancer risk but doesn&#39;t create the immediate proliferative danger that active malignancy does. Standard screening protocols apply: annual mammography for women over 40 with breast cancer family history, colonoscopy starting at age 45 (or 10 years before the youngest affected relative&#39;s diagnosis), and PSA testing for men over 50 with prostate cancer family history. If screening reveals pre-malignant lesions (colon polyps, atypical ductal hyperplasia), delay sermorelin until those lesions are removed and surveillance confirms no progression.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m Diabetic but My HbA1c Is Well-Controlled at 6.8%?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Well-controlled diabetes (HbA1c below 7.5%) is not a sermorelin contraindication. It&#39;s a condition requiring dose monitoring and ophthalmology clearance before starting therapy. Growth hormone&#39;s anti-insulin effects are dose-dependent and reversible, meaning your diabetes management team can adjust insulin or oral hypoglycaemic agents to compensate for the metabolic shift sermorelin creates. The critical screening step is a dilated fundoscopic exam to rule out proliferative retinopathy. Non-proliferative retinopathy (mild background changes, microaneurysms, hard exudates) doesn&#39;t prohibit sermorelin but does require 6-month ophthalmology follow-up during therapy. If your last eye exam was more than 12 months ago, schedule a comprehensive retinal evaluation before starting sermorelin. This is standard medical practice, not overcaution.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Had Thyroid Cancer 10 Years Ago and I&#39;m Still on Levothyroxine?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Thyroid cancer with complete remission exceeding five years and undetectable thyroglobulin levels (the tumour marker for recurrence) is not an absolute sermorelin contraindication. But it requires oncology and endocrinology clearance before proceeding. The relevant question is whether your thyroid cancer was papillary or follicular (low-risk, rarely recurs after successful treatment) or medullary or anaplastic (higher recurrence risk, longer surveillance required). Papillary thyroid cancer treated with total thyroidectomy and radioactive iodine ablation, with undetectable thyroglobulin and negative ultrasound surveillance for 10 years, carries minimal recurrence risk. Most endocrinologists would clear sermorelin use in this scenario. Medullary thyroid cancer requires calcitonin monitoring and longer surveillance periods before considering growth hormone secretagogue therapy.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Develop Severe Hyperglycaemia After Starting Sermorelin?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Severe hyperglycaemia (fasting glucose above 250 mg\/dL or random glucose above 350 mg\/dL) during sermorelin therapy requires immediate dose reduction or temporary discontinuation. Growth hormone&#39;s anti-insulin effect peaks 4\u20136 hours post-injection and resolves within 24 hours, meaning hyperglycaemic episodes correlate with injection timing. The clinical decision pathway: if glucose elevation is mild (180\u2013220 mg\/dL fasting), increase basal insulin by 10\u201320% and continue sermorelin at the same dose; if glucose exceeds 250 mg\/dL fasting or you experience polyuria, polydipsia, or ketones on urine testing, hold sermorelin for 48\u201372 hours and contact your prescriber immediately. Type 1 diabetics are at higher risk for this complication than type 2 diabetics because they lack endogenous insulin reserve to compensate for GH-induced insulin resistance.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Unfiltered Truth About Sermorelin Contraindications<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: sermorelin contraindication screening in telehealth settings is inconsistent at best and dangerously superficial at worst. The standard intake form asks &#39;Do you have cancer?&#39; and &#39;Are you diabetic?&#39;. Binary questions that miss the entire clinical context. A patient who had stage I breast cancer treated 6 years ago answers &#39;no&#39; to the cancer question because they consider themselves cured, but oncology guidelines still classify them as requiring clearance before growth hormone secretagogue therapy. A type 2 diabetic with HbA1c of 9.2% who hasn&#39;t seen an ophthalmologist in three years answers &#39;yes&#39; to diabetes but gets cleared for sermorelin anyway because the intake form doesn&#39;t ask about retinopathy status or glycaemic control. We&#39;ve seen both patterns repeatedly. Patients who should have been screened more thoroughly but weren&#39;t, and patients who were unnecessarily denied therapy because the prescriber applied blanket contraindications without understanding relative versus absolute risk categories. The gap isn&#39;t malice. It&#39;s the structural limitation of asynchronous telemedicine models that can&#39;t replicate the depth of an in-person medical history and physical examination.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Managing Borderline Cases \u2014 When Contraindications Aren&#39;t Absolute<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Clinical decision-making around sermorelin contraindications becomes nuanced when patients fall into grey zones: the 58-year-old with mild non-proliferative diabetic retinopathy and HbA1c of 7.8%; the 45-year-old with stage I colon cancer treated 4.5 years ago who&#39;s eager to start anti-aging therapy; the 52-year-old with subclinical hypothyroidism (TSH 5.2 mIU\/L) and normal free T4 who wants sermorelin for body composition improvement. These cases require risk stratification rather than blanket approval or denial.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The framework we use: (1) Quantify the contraindication severity using objective markers (HbA1c, TSH, time since cancer remission, retinopathy stage). (2) Assess the clinical urgency of sermorelin therapy. Is this medically indicated (adult growth hormone deficiency, HIV-associated wasting) or elective (anti-aging, body composition)? (3) Determine whether the contraindication can be mitigated through pre-treatment optimization (improving glycaemic control, normalizing thyroid function, obtaining oncology clearance). (4) Establish monitoring parameters that allow early detection of adverse effects (monthly HbA1c during titration, ophthalmology exams every 6 months, tumour marker surveillance). Patients with relative contraindications who undergo thorough pre-treatment optimization and consent to closer monitoring can often use sermorelin safely. But that requires prescriber engagement beyond what most telehealth platforms provide.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Another layer of complexity: drug interactions that create functional contraindications even when the underlying medical condition isn&#39;t listed. Glucocorticoids (prednisone, dexamethasone, hydrocortisone) suppress growth hormone secretion and IGF-1 synthesis, rendering sermorelin ineffective. Patients on chronic corticosteroid therapy for autoimmune conditions, inflammatory bowel disease, or COPD will see minimal sermorelin response until steroid doses are tapered below physiological replacement levels (5\u20137.5 mg prednisone equivalent daily). Oestrogen replacement therapy. Whether oral contraceptives or menopausal hormone therapy. Increases hepatic production of IGF-binding proteins, which reduces free (bioavailable) IGF-1 levels and blunts sermorelin&#39;s anabolic effects. These aren&#39;t contraindications in the strictest sense, but they represent scenarios where sermorelin is unlikely to produce meaningful clinical benefit without dose adjustments or medication changes.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The ultimate question for borderline cases: does the potential benefit justify the monitoring burden and residual risk? For a patient with adult growth hormone deficiency confirmed by stimulation testing. Fatigue, reduced bone density, sarcopenia, elevated cardiovascular risk. The answer is often yes. For a healthy 50-year-old seeking modest improvements in muscle mass and sleep quality, the calculus shifts. Sermorelin isn&#39;t a benign supplement; it&#39;s a pharmacologically active peptide that requires medical oversight proportional to the risk profile it creates.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If you&#39;re navigating sermorelin eligibility and have medical conditions that fall into relative contraindication territory, the path forward is specialist evaluation before starting therapy. Not hoping a telehealth provider will clear you based on an intake form. At TrimRx, we require comprehensive metabolic panels, thyroid function testing, and ophthalmology clearance for diabetic patients precisely because sermorelin contraindications aren&#39;t hypothetical. They&#39;re evidence-based guardrails that prevent genuine harm when applied correctly. The right provider doesn&#39;t minimize contraindications to close a sale; they use them as decision tools that protect patient safety while maximizing therapeutic benefit for those who truly qualify.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can I use sermorelin if I had cancer 10 years ago?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Cancer history exceeding five years post-remission is generally not an absolute sermorelin contraindication, but oncology clearance is required before starting therapy. The specific cancer type matters: low-risk cancers like early-stage papillary thyroid carcinoma or localized prostate cancer treated successfully have minimal recurrence risk after 10 years, while higher-risk malignancies like triple-negative breast cancer or stage III colon cancer require longer surveillance periods and tumour marker monitoring. Your oncologist will assess current disease-free status through imaging, bloodwork, and physical examination before clearing sermorelin use.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">What happens if I start sermorelin and then discover I&#8217;m pregnant?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Discontinue sermorelin immediately upon confirmed pregnancy and contact your prescribing physician. Pregnancy is an absolute sermorelin contraindication due to insufficient human safety data and theoretical risk of altering foetal growth patterns through placental IGF-1 transfer. No controlled trials have assessed sermorelin safety during pregnancy, and the compound carries Pregnancy Category C classification. Women of childbearing age should use reliable contraception during sermorelin therapy and perform pregnancy testing if menses are delayed before continuing treatment.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Is diabetes an automatic disqualification for sermorelin therapy?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Diabetes is not an automatic sermorelin contraindication \u2014 eligibility depends on glycaemic control and retinopathy status. Well-controlled diabetes (HbA1c below 7.5%, no proliferative retinopathy) permits sermorelin use with dose adjustments to insulin or oral hypoglycaemic agents and ophthalmology clearance. Uncontrolled diabetes (HbA1c above 8.5%) or proliferative diabetic retinopathy are contraindications requiring optimization before therapy initiation. Growth hormone opposes insulin action, so diabetic patients need closer glucose monitoring during sermorelin titration to prevent hyperglycaemic episodes.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can hypothyroidism prevent me from using sermorelin effectively?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Untreated or undertreated hypothyroidism reduces sermorelin efficacy because thyroid hormone is required for normal growth hormone receptor expression and IGF-1 synthesis. Patients with TSH above 4.5 mIU\/L experience blunted response to sermorelin therapy. The solution is optimizing levothyroxine dose first \u2014 target TSH below 3.0 mIU\/L \u2014 then initiating sermorelin once euthyroid status is confirmed. Concurrent thyroid hormone and sermorelin therapy is safe and effective once thyroid function normalizes, making hypothyroidism a relative contraindication requiring pre-treatment correction rather than permanent disqualification.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Do I need an eye exam before starting sermorelin if I&#8217;m diabetic?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Diabetic patients require a dilated fundoscopic examination by an ophthalmologist before starting sermorelin to rule out proliferative retinopathy. Proliferative diabetic retinopathy \u2014 characterized by abnormal blood vessel growth on the retinal surface \u2014 is an absolute sermorelin contraindication because IGF-1 promotes further neovascularisation and increases vitreous haemorrhage risk. Non-proliferative retinopathy (earlier-stage microvascular changes) permits sermorelin use with 6-month ophthalmology follow-up during therapy. This screening requirement applies to all diabetic patients regardless of diabetes type or duration \u2014 vision-threatening complications develop silently and require professional examination to detect.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">What if my cancer was treated more than 5 years ago but I still take tamoxifen?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Ongoing adjuvant endocrine therapy (tamoxifen, aromatase inhibitors) for breast cancer does not automatically contraindicate sermorelin, but it does require oncology clearance and careful risk assessment. The five-year remission threshold applies to treatment completion, not diagnosis date. If you&#8217;re still taking tamoxifen or letrozole as part of extended adjuvant therapy, your oncologist must confirm current disease-free status through imaging and tumour markers before clearing sermorelin. Most medical oncologists recommend waiting until endocrine therapy is complete before adding growth hormone secretagogues to minimize any theoretical risk of stimulating dormant micrometastases.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can sermorelin worsen my insulin resistance if I have prediabetes?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin can transiently increase insulin resistance through growth hormone&#8217;s anti-insulin effects, but the magnitude is modest in non-diabetic patients and reversible upon discontinuation. Prediabetes (HbA1c 5.7\u20136.4% or fasting glucose 100\u2013125 mg\/dL) is not a sermorelin contraindication, but it warrants baseline and 3-month follow-up HbA1c testing to monitor glycaemic trends. Most prediabetic patients tolerate sermorelin without progression to overt diabetes, especially when combined with dietary modification and exercise. The clinical concern is unmasking previously undiagnosed type 2 diabetes in patients with significant insulin resistance at baseline.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Why is critical illness a contraindication if growth hormone helps healing?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Critical illness creates a state of growth hormone resistance \u2014 elevated circulating GH with paradoxically low IGF-1 levels \u2014 making sermorelin ineffective and metabolically unpredictable during acute stress. The body&#8217;s catabolic response to sepsis, trauma, or major surgery suppresses GH receptor expression and hepatic IGF-1 synthesis as an adaptive mechanism. Administering sermorelin during this phase produces no therapeutic benefit because the GH-IGF-1 axis is already maximally stressed. The contraindication is temporary; sermorelin can be initiated 4\u20136 weeks post-discharge from ICU-level care once metabolic homeostasis is restored and the acute-phase response resolves.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can I take sermorelin if I have a history of pituitary tumour surgery?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Prior pituitary surgery is not an absolute sermorelin contraindication but does raise questions about residual pituitary function and somatotroph cell mass. Sermorelin requires functional pituitary tissue to produce endogenous growth hormone \u2014 patients with significant pituitary damage from surgery, radiation, or tumour compression may not respond to GHRH stimulation. Pre-treatment evaluation should include IGF-1 and IGFBP-3 levels, and ideally a GH stimulation test to confirm adequate pituitary reserve. If stimulation testing demonstrates preserved GH secretory capacity, sermorelin can be used safely; if testing shows blunted response, exogenous GH replacement may be more appropriate than a secretagogue.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Does sermorelin increase cancer risk in people with no cancer history?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">No robust evidence supports increased de novo cancer risk from sermorelin or growth hormone therapy in patients without pre-existing malignancy. Long-term observational studies of adults receiving GH replacement for pituitary insufficiency show cancer incidence rates similar to age-matched controls. The contraindication for active malignancy exists because IGF-1 accelerates growth of existing cancer cells \u2014 not because it initiates carcinogenesis in healthy tissue. Theoretical concerns about IGF-1 and cancer stem from epidemiological associations showing higher cancer rates in populations with elevated baseline IGF-1, but causality has not been established and confounding factors (obesity, insulin resistance) likely explain much of that association.<\/p>\n<\/div>\n<\/details>\n<style>\n.faq-item summary { outline: none; }\n.faq-item summary::-webkit-details-marker { display: none; }\n.faq-item[open] .faq-arrow { transform: rotate(180deg); }\n<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sermorelin contraindications include active cancer, uncontrolled diabetes, and pregnancy. Learn who should avoid this peptide and why in this detailed<\/p>\n","protected":false},"author":6,"featured_media":77412,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-77413","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=77413"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77413\/revisions"}],"predecessor-version":[{"id":77414,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77413\/revisions\/77414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/77412"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=77413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=77413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=77413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}